All In Biotech

Drug Trial Radar · NCT05800873

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

A Phase 1b/2 Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 In Participants With Selected Proteinuric Glomerular Diseases

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31

Actual

Start

May 15, 2023

Primary completion

Jul 27, 2026

Study completion Jul 27, 2026

Sponsor

Sponsor type
Industry
First posted
Apr 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases. The overall aim of the study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of EVER001 in subjects with selected proteinuric glomerular diseases. The first targeted disease is primary membranous nephropathy.

Conditions

  • Primary Membranous Nephropathy

Interventions

  • EVER001Drug

    A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.

  • EVER001Drug

    A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. adverse eventsTime frame: 104 weeks.
  2. clinical laboratory assessments.Time frame: 104 weeks.
  3. vital signs.Time frame: 104 weeks.
  4. physical examinationTime frame: 104 weeks
  5. ECG.Time frame: 104 weeks.

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China

  • The Second Xiangya Hospital Of Central South University

    Changsha, Changsha, China

  • The First Affiliated Hospital of PLA Army Medical University

    Chongqing, Chongqing Municipality, China

  • The Third Affiliated Hospital,Sun Yat Sen University

    Guangzhou, Guangdong, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Harbin, China

  • Xiangya Third Hospital, Central South University

    Changsha, Hunan, China

  • The First Affiliated Hospital of Baotou Medical College

    Baotou, Inner Mongolia, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital of Medical college of Xi'an Jiaotong University

    Xian, Shanxi, China

  • Sichuan Province People's Hospital

    Chengdu, Sichuan, China

  • Second Hospital of Shanxi Medical University

    Shanxi, Taiyuan, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

  • The first affliated hospital of NingBo university

    Ningbo, Zhejiang, China

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.